Repligen Corporation is a bioprocessing company that provides innovative products and solutions for the life sciences industry. The company was founded in 1981 and is headquartered in Waltham, Massachusetts, USA. Repligen's early focus was on developing technologies for the production of monoclonal antibodies, a type of therapeutic protein used in biopharmaceuticals.
Repligen's primary mission is to support biopharmaceutical companies in their efforts to develop and manufacture advanced therapies and medicines. The company offers a diverse portfolio of products and technologies designed to enhance the process of bioproduction, from cell line development to final product purification.
One of Repligen's key product lines is its Protein A affinity resins, which are widely used in the purification of monoclonal antibodies and other biologics. The company's innovative technologies help improve productivity, yield, and efficiency in biopharmaceutical manufacturing, ultimately contributing to the development of life-saving therapies.
Repligen has a global presence, with offices and facilities in the United States, Europe, and Asia. The company serves a diverse customer base, including pharmaceutical and biotechnology companies, research institutions, and contract manufacturing organizations.
In addition to its products, Repligen offers process development and technical support services to assist customers in optimizing their bioproduction processes. The company's team of experts works closely with clients to provide tailored solutions and ensure successful biomanufacturing outcomes.